Brazilian Journal of Anesthesiology
https://bjan-sba.org/article/doi/10.1016/j.bjane.2017.10.008
Brazilian Journal of Anesthesiology
Clinical Information

Reversal of neuromuscular block with sugammadex in five heart transplant pediatric recipients

Reversão do bloqueio neuromuscular com sugamadex em cinco receptores pediátricos de transplante cardíaco

Ricardo Vieira Carlos; Marcelo Luis Abramides Torres; Hans Donald de Boer

Downloads: 0
Views: 641

Abstract

Abstract Heart transplantation is a frequent procedure in the treatment of end-stage cardiac dysfunction. Therefore, these patient populations will also be more frequent exposed to other more common surgical procedures after their transplantation. Anesthesiologist should be aware in their assessment of these patients, especially regarding some specific issues related to patients with a history of heart transplantation, like reversal of neuromuscular block. Several reports described that cholinesterase inhibitors drugs, like neostigmine, may produce a dose-dependent life-threatening bradycardia in heart transplant recipients while other publication described the safe use of neostigmine. Reversal of neuromuscular block with sugammadex is another possibility, but limited data exists in literature. We describe five cases in which successful reversal of neuromuscular block was performed with sugammadex in heart transplant pediatric recipients without sequale and discuss the reversal of neuromuscular block in this patient population.

Keywords

Rocuronium, Sugammadex, Cardiac transplantation, Reversal of neuromuscular block

Resumo

Resumo O transplante cardíaco é um procedimento frequente no tratamento da disfunção cardíaca em estágio final. Portanto, essa população de pacientes também será exposta com mais frequência a outros procedimentos cirúrgicos mais comuns após o transplante. Em sua avaliação, o anestesiologista deve ter em mente algumas questões específicas relacionadas à história de transplante cardíaco desses pacientes, tais como a reversão do bloqueio neuromuscular. Vários estudos relataram que os inibidores da colinesterase, como a neostigmina, podem produzir uma bradicardia dose-dependente que ameaça a vida em receptores de transplante cardíaco, enquanto um estudo relatou o uso seguro de neostigmina. A reversão do bloqueio neuromuscular com sugamadex é outra possibilidade, mas os dados na literatura são escassos. Descrevemos cinco casos nos quais a reversão bem-sucedida do bloqueio neuromuscular foi realizada com sugamadex em receptores pediátricos de transplante cardíaco sem deixar sequelas e discutimos a reversão do bloqueio neuromuscular nessa população de pacientes.

Palavras-chave

Rocurônio, Sugammadex, Transplante cardíaco, Reversão do bloqueio neuromuscular

References

Anesthesia for cardiac surgical procedures. 2015:2007-295.

Arbous MS, Meursing AEE, van Kleef JW. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005;102:257-68.

Murphy GS, Szokol JW, Marymont JH. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130-7.

Grosse-Sundrup M, Henneman JP, Sandberg WS. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329.

Barbara DW, Christensen JM, Mauermann WJ. The safety of neuromuscular block reversal in patients with cardiac transplantation. Transplantation. 2016;100:2723-8.

Bertolizio G, Yuki K, Odegard K. Cardiac arrest and neuromuscular blockade reversal agents in the transplanted heart. J Cardiothorac Anesth. 2013;27:1374-8.

Beebe DS, Shumway SJ, Maddock R. Sinus arrest after intravenous neostigmine in two heart transplant recipients. Anesth Analg. 1994;78:779-82.

Bjerke RJ, Mangione MP. Asystole after intravenous neostigmine in a heart transplant recipient. Can J Anaesth. 2001;48:305-7.

Sawasdiwipachai P, Laussen PC, McGowan FX. Cardiac arrest after neuromuscular blockade reversal in heart transplant infant. Anesthesiology. 2007;107:663-5.

Gomez-Rios MA, Lopez LR. Use of combination of rocuronium and sugammadex in heart transplant recipients. Anaesth Intensive Care. 2012;40:903-4.

Tezcan B, Saylan A, Bolukbasi D. Use of sugammadex in a heart transplant recipient: review of the unique physiology of the transplanted heart. J Cardiothorac Anesth. 2016;30:462-5.

Fuchs-Buder T, Claudius C, Skovgaard LT. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789-808.

Backman SB, Fox GS, Stein RD. Neostigmine decreases heart rate in heart transplant patients. Can J Anaesth. 1996;43:373-8.

Dahl V, Pendeville PE, Hollmann MW. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26:874-84.

De Kam PJ, van Kuijk J, Prohn M. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough study. Clin Drug Investig. 2010;30:599-611.

De Kam PJ, van Kuijk J, Smeets J. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. Int J Clin Pharmacol Ther. 2012;50:595-604.

5dcc2ee30e88252b02bf58f2 rba Articles
Links & Downloads

Braz J Anesthesiol

Share this page
Page Sections